Adaptin Bio (APTN) Equity Average (2023 - 2026)

Adaptin Bio has disclosed Equity Average across 4 years of filings, most recently posting -$1.6 million for Q1 2026.

• Quarterly Equity Average fell 38.65% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.6 million (down 38.65% YoY) and the FY2025 annual result came in at -$2.8 million, down 10.08% from the prior year.
• Equity Average retreated to -$1.6 million in Q1 2026, from -$1.2 million in the prior quarter.
• Across five years, Equity Average topped out at $1.1 million in Q2 2025 and bottomed at -$3.7 million in Q4 2024.
• The 4-year median for Equity Average is -$1.1 million (2024), against an average of -$997847.2.
• Year-over-year, Equity Average sank 5025.92% in 2024 and soared 164.29% in 2025.
• Adaptin Bio's Equity Average stood at -$528150.5 in 2023, then sank by 595.2% to -$3.7 million in 2024, then soared by 67.72% to -$1.2 million in 2025, then plunged by 37.73% to -$1.6 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered -$1.6 million, -$1.2 million, and -$203334.5 for Q1 2026, Q4 2025, and Q3 2025 respectively.